Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura L. Kaynar; P. Coppo; M. Scully; J. De La Rubia; F. Peyvandi; S. Cataland; J. A. Kremer Hovinga; P. Knoebl; K. Pavenski; J. Minkue Mi Edou; F. Callewaert; R. De Passos Sousa;

OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DESPITE DAILY THERAPEUTIC PLASMA EXCHANGE IN THE PHASE 3 HERCULES TRIAL M. Scully; J.L. Rubia; F. Peyvandi; S. Cataland; P. Coppo; J.A.K. Hovinga; P. Knoebl; K. Pavenski; F. Callewaert; J.M.M. Edou; R.P. Sousa;